Toxoplasma Infection

Sulfadiazine is an orally active sulfonamide antibiotic. Sulfadiazine competitively inhibits p-aminobenzoic acid in the folic-acid-metabolism cycle, inhibiting multiplication of most Gram-positive and many Gram-negative bacteria. Sulfadiazine persists in soil long-term, and exerts selective pressure for sulfonamide-resistant microbial populations. Sulfadiazine targets Toxoplasma gondii DHPS enzyme. Sulfadiazine can be used for the research of congenital toxoplasmosis and bacterial infection.

Calcitetrol (1α, 24, 25-Trihydroxy VD3), a Vitamin D3 (HY-15398) metabolite, is the hormonally active form of vitamin D. Calcitetrol participates in regulation of Treg cells. Calcitetrol can be used for the research of Toxoplasma gondii infection.

Myrislignan is a PI3K/AKT/NF-κB inhibitor that can cross the blood-brain barrier. Myrislignan exerts anticancer activity by inducing apoptosis and ferroptosis. Myrislignan inhibits the replication and invasion of Toxoplasma gondii; it induces reactive oxygen species (ROS) imbalance, autophagy, and the death of Toxoplasma gondii tachyzoites. Myrislignan inhibits mitochondrial function and ERK1/2 phosphorylation to improve ovariectomy-induced osteoporosis. Myrislignan can be used in studies related to gastric cancer, glioblastoma, osteoporosis, and toxoplasmosis.

CWHM-117 is an orally active aspartic protease inhibitor with selective activity against Toxoplasma gondii. CWHM-117 inhibits the proliferation of Toxoplasma gondii tachyzoites in human fibroblasts, with an EC₅₀ of 2.00 µM. CWHM-117 delays mortality in an acute mouse model of toxoplasmosis. In a chronic mouse model of toxoplasmosis, CWHM-117 reduces brain cyst burden and prolongs survival. CWHM-117 can be used for research on toxoplasmosis.

DHFR-IN-27 (Compound LA4) is an orally active DHFR inhibitor and antimalarial agent, with a K_i value of 1.71 nM against TgDHFR. DHFR-IN-27 reduces the parasitic load of Toxoplasma gondii in infected mice and prolongs the survival time of infected mice. DHFR-IN-27 exerts Antiparasitic effects against Toxoplasma gondii. DHFR-IN-27 can be used in the research of toxoplasmosis.

NCR247 is a defensin-like nodule cysteine-rich (NCR) peptide and heme chelator. NCR247 induces iron starvation responses in Sinorhizobium meliloti and Medicago truncatula, and supports nitrogenase activity. NCR247 can be used in research related to periodontal disease and toxoplasmosis.

Sulfadiazine 100 µg/mL in methanol is an orally active sulfonamide antibiotic. Sulfadiazine 100 µg/mL in methanol competitively inhibits p-aminobenzoic acid in the folic-acid-metabolism cycle, inhibiting multiplication of most Gram-positive and many Gram-negative bacteria. Sulfadiazine 100 µg/mL in methanol persists in soil long-term, and exerts selective pressure for sulfonamide-resistant microbial populations. Sulfadiazine 100 µg/mL in methanol targets Toxoplasma gondii DHPS enzyme. Sulfadiazine 100 µg/mL in methanol can be used for the research of congenital toxoplasmosis and bacterial infection.

Myrislignan-13C,d2 is the ¹³C, d₂ deuterated-labeled Myrislignan (HY-N0608). Myrislignan is a PI3K/AKT/NF-κB inhibitor that can cross the blood-brain barrier. Myrislignan exerts anticancer activity by inducing apoptosis and ferroptosis. Myrislignan inhibits the replication and invasion of Toxoplasma gondii; it induces reactive oxygen species (ROS) imbalance, autophagy, and the death of Toxoplasma gondii tachyzoites. Myrislignan inhibits mitochondrial function and ERK1/2 phosphorylation to improve ovariectomy-induced osteoporosis. Myrislignan can be used in studies related to gastric cancer, glioblastoma, osteoporosis, and toxoplasmosis.

Kijimicin is a polyether ionophore antibiotic originally discovered in Actinomadura sp. MI215-NF3. inhibits HIV-1 replication and reduces the infectivity of progeny viral particles. Kijimicin exhibits inhibitory activity against intracellular T. gondii (IC₅₀ = 45.6 nM), extracellular parasites (IC₅₀ = 216.6 pM) and C. parvum (IC₅₀ = 7.7 nM), and controls acute T. gondii infection in mice. Kijimicin can be used for research on HIV, toxoplasmosis, cryptosporidiosis, and bacterial infections.

Kijimicin sodium is a polyether ionophore antibiotic originally discovered in Actinomadura sp. MI215-NF3. Kijimicin sodium inhibits HIV-1 replication and reduces the infectivity of progeny viral particles. Kijimicin sodium exhibits inhibitory activity against intracellular T. gondii (IC₅₀ = 45.6 nM), extracellular parasites (IC₅₀ = 216.6 pM) and C. parvum (IC₅₀ = 7.7 nM), and controls acute T. gondii infection in mice. Kijimicin sodium can be used for research on HIV, toxoplasmosis, cryptosporidiosis, and bacterial infections.

TgCDPK1-IN-1 is an orally active, blood-brain barrier-permeable TgCDPK1 inhibitor (IC₅₀ = 15.7 nM) with antiparasitic activity against Toxoplasma gondii. TgCDPK1-IN-1 inhibits Src and TgCDPK^G128M. TgCDPK1-IN-1 cures acute toxoplasmosis in immunocompetent mice and prolongs the survival of immunocompromised mice. TgCDPK1-IN-1 is applicable for research related to toxoplasmosis.

GSK2188764 is a Toxoplasma gondii rhoptry protein 18 (ROP18) inhibitor with reported IC₅₀ values of 7.49 μM against Toxoplasma gondii. GSK2188764 inhibits serine-threonine kinase activity of ROP18 in vitro.GSK2188764 can be used for the research of toxoplasmosis.